Dambkowski Carl 4
4 · Apogee Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Apogee (APGE) CMO Carl Dambkowski Exercises Options, Sells Shares
What Happened
- Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), exercised options to acquire 4,125 shares at $22.86 per share (cost $94,298) on February 4, 2026. On the same date he sold a total of 5,500 shares in open-market transactions for aggregate gross proceeds of about $361,860 (sales at weighted average prices ranging from $64.24 to $68.98 per share across multiple trades). The filing also shows a disposition of 4,125 shares at $0 (derivative entry) related to the exercise.
- These actions include both an option exercise (M) and multiple sales (S). Sales are routine insider disposition activity; the exercise is an acquisition of shares by exercising a derivative right.
Key Details
- Transaction date: February 4, 2026 (Form filed same day).
- Option exercise: 4,125 shares acquired at $22.86 each = $94,298.
- Open-market sales: 5,500 shares sold in multiple trades for total proceeds ≈ $361,860 (individual blocks: 2,481 @ ~$64.88; 1,420 @ ~$65.83; 1,299 @ ~$66.85; 100 @ ~$67.88; 200 @ ~$68.94; reported as weighted averages with ranges in footnotes).
- Derivative disposition: 4,125 shares reported disposed at $0 (listed as M/derivative in filing).
- Footnotes: F1 — sales executed under a Rule 10b5-1 trading plan adopted Sept 22, 2025. F2–F6 — reported sale prices are weighted averages with per-trade price ranges (ranges provided in filing). F7 — the option pool referenced covers 175,345 shares that vest monthly through Dec 18, 2027.
- Shares owned after the transactions: not specified in the summary information provided in your request (refer to the Form 4 for post-transaction beneficial ownership).
- Filing timeliness: filed for the same date as the transactions (no late filing indicated).
Context
- The filing shows an option exercise plus contemporaneous sales. The separate line showing a disposition of 4,125 shares at $0 commonly reflects a net share settlement, surrender, or similar administrative action connected to the exercise (e.g., to cover exercise cost or taxes); check the full Form 4 footnotes for issuer-specific details.
- Sales executed under a 10b5-1 plan indicate pre-scheduled transactions — this is routine and not direct evidence of sentiment. Purchases (exercises) can be meaningful, but in this case many shares were sold the same day or reported under plan-driven sales.
Insider Transaction Report
Form 4
Dambkowski Carl
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2026-02-04$22.86/sh+4,125$94,298→ 216,648 total - Sale
Common Stock
[F1][F2]2026-02-04$64.88/sh−2,481$160,967→ 214,167 total - Sale
Common Stock
[F1][F3]2026-02-04$65.83/sh−1,420$93,479→ 212,747 total - Sale
Common Stock
[F1][F4]2026-02-04$66.85/sh−1,299$86,838→ 211,448 total - Sale
Common Stock
[F1][F5]2026-02-04$67.88/sh−100$6,788→ 211,348 total - Sale
Common Stock
[F1][F6]2026-02-04$68.94/sh−200$13,788→ 211,148 total - Exercise/Conversion
Stock Option (Right to Buy)
[F7]2026-02-04−4,125→ 135,415 totalExercise: $22.86Exp: 2033-12-18→ Common Stock (4,125 underlying)
Footnotes (7)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.24 to $65.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.27 to $66.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.37 to $67.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.80 to $67.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.90 to $68.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F7]This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.
Signature
/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski|2026-02-04